Also categorized in Clinical Research:
A Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
x hide permanently

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

ncbi.nlm.nih.gov

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

Oncoimmunology. 2017;6(11):e1358331

Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

Mentions: Antibody